Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 51 to 82 of 82 results for bevacizumab

  1. Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer (TA285)

    Evidence-based recommendations on bevacizumab (Avastin), with gemcitabine and carboplatin, for treating platinum-sensitive advanced ovarian cancer in adults.

    Technology appraisal guidance
    Published
    22 May 2013
    View recommendations

    Sections for TA285

  2. Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (TA263)

    Evidence-based recommendations on bevacizumab (Avastin), with capecitabine, for treating metastatic breast cancer in adults.

    Technology appraisal guidance
    Published
    22 August 2012
    View recommendations

    Sections for TA263

  3. Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (TA242)

    Evidence-based recommendations on cetuximab (Erbitux), bevacizumab (Avastin) and panitumumab (Vectibix) for treating metastatic colorectal cancer in adults.

    Technology appraisal guidance
    Published
    25 January 2012
    View recommendations

    Sections for TA242

  4. Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118)

    Evidence-based recommendations on bevacizumab (Avastin) and cetuximab (Erbitux) for treating metastatic colorectal cancer in adults.

    Technology appraisal guidance
    Last updated
    1 January 2012
    View recommendations

    Sections for TA118

  5. Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion (TA229)

    Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating macular oedema following retinal vein occlusion in adults.

    Technology appraisal guidance
    Published
    27 July 2011
    View recommendations

    Sections for TA229

  6. Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (TA214)

    Evidence-based recommendations on bevacizumab (Avastin), with a taxane, for treating metastatic breast cancer in adults.

    Technology appraisal guidance
    Published
    23 February 2011
    View recommendations

    Sections for TA214

  7. Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (TA212)

    Evidence-based recommendations on bevacizumab (Avastin), with other drugs, for treating metastatic colorectal cancer in adults.

    Technology appraisal guidance
    Published
    15 December 2010
    View recommendations

    Sections for TA212

  8. Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (TA178)

    Evidence-based recommendations on bevacizumab (Avastin), sorafenib (Nexavar), sunitinib (Sutent) and temsirolimus (Torisel) for treating advanced or metastatic renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    26 August 2009
    View recommendations

    Sections for TA178

  9. Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal) (TA148)

    NICE is unable to recommend the use in the NHS of bevacizumab in addition to platinum-based chemotherapy for the first-line treatment of patients with unresectable advanced, metastatic or recurrent non-small-cell lung cancer (other than predominantly squamous cell histology) because no evidence submission was received from the manufacturer or sponsor of the technology.

    Technology appraisal guidance
    Published
    25 June 2008

    Sections for TA148

  10. Bevacizumab for the first-line treatment of metastatic breast cancer (TA147)

    This appraisal has been updated and replaced by NICE technology appraisal 214.

    Technology appraisal guidance
    Published
    25 June 2008

  11. Bevacizumab for untreated malignant pleural mesothelioma [ID1183]

    Discontinued [GID-TA10197]

    Technology appraisal guidance
    Discontinued

  12. Bevacizumab for treating recurrent glioblastoma [ID978]

    Discontinued [GID-TA10149]

    Technology appraisal guidance
    Discontinued

  13. Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]

    In development [GID-TAG388] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]

    In development [GID-TAG406] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Erlotinib in combination with bevacizumab for the maintenance treatment of advanced or metastatic non-small cell lung cancer [ID44]

    Discontinued [GID-TA11206]

    Technology appraisal guidance
    Discontinued

  16. Erlotinib in combination with bevacizumab for the second line treatment of advanced or metastatic non-small cell lung cancer [ID43]

    Discontinued [GID-TA11207]

    Technology appraisal guidance
    Discontinued

  17. Bevacizumab for the treatment of recurrent glioblastoma multiforme [ID80]

    Discontinued [GID-TAG413]

    Technology appraisal guidance
    Discontinued

  18. Bevacizumab in combination with chemotherapy for the second line treatment of HER2 negative metastatic breast cancer [ID488]

    Discontinued [GID-TAG432]

    Technology appraisal guidance
    Discontinued

  19. Atezolizumab in combination for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in people who have not received any prior systemic therapy [ID2700]

    Discontinued [GID-TA10574]

    Technology appraisal guidance
    Discontinued

  20. Nivolumab for treating recurrent glioblastoma [ID998]

    Discontinued [GID-TA10126]

    Technology appraisal guidance
    Discontinued

  21. Exploratory work regarding the use of bevacizumab in the treatment of eye conditions [ID422]

    Discontinued [GID-TA11205]

    Technology appraisal guidance
    Discontinued

  22. Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701

    In development [GID-TA11157] Expected publication date: TBC

    Technology appraisal guidance
    In development

  23. Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma TS ID 10736

    Awaiting development [GID-TA11076] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  24. Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]

    In development [GID-TA10900] Expected publication date: TBC

    Technology appraisal guidance
    In development

  25. Durvalumab (Imfinzi) with bevacizumab (Avastin) for high-risk adjuvant hepatocellular carcinoma [ID6146]

    Awaiting development [GID-TA11222] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  26. Atezolizumab for untreated advanced renal cell carcinoma [ID1365]

    Discontinued [GID-TA10338]

    Technology appraisal guidance
    Discontinued

  27. Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944]

    Awaiting development [GID-TA10911] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  28. Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148]

    In development [GID-TA11074] Expected publication date: TBC

    Technology appraisal guidance
    In development

  29. Treatments for non-small-cell lung cancer [ID6234]

    In development [GID-TA11289] Expected publication date: TBC

    Technology appraisal guidance
    In development

  30. Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments [ID6298]

    In development [GID-TA11390] Expected publication date: 24 July 2024

    Technology appraisal guidance
    In development

  31. Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence ID6428

    Awaiting development [GID-TA11538] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  32. Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (MA review of TA760) [ID6293]

    In development [GID-TA11480] Expected publication date: 13 November 2024

    Technology appraisal guidance
    In development